316 related articles for article (PubMed ID: 23730262)
41. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
42. Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age.
Śmiałek D; Kotulska K; Duda A; Jóźwiak S
Neurol Ther; 2023 Jun; 12(3):931-946. PubMed ID: 37085686
[TBL] [Abstract][Full Text] [Related]
43. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
Bissler JJ; Franz DN; Frost MD; Belousova E; Bebin EM; Sparagana S; Berkowitz N; Ridolfi A; Kingswood JC
Pediatr Nephrol; 2018 Jan; 33(1):101-109. PubMed ID: 28993887
[TBL] [Abstract][Full Text] [Related]
44. An update on the central nervous system manifestations of tuberous sclerosis complex.
Cotter JA
Acta Neuropathol; 2020 Apr; 139(4):613-624. PubMed ID: 30976976
[TBL] [Abstract][Full Text] [Related]
45. Management of side effects of mTOR inhibitors in tuberous sclerosis patients.
Sadowski K; Kotulska K; Jóźwiak S
Pharmacol Rep; 2016 Jun; 68(3):536-42. PubMed ID: 26891243
[TBL] [Abstract][Full Text] [Related]
46. Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis.
Kim WS
Korean J Pediatr; 2011 Jun; 54(6):241-5. PubMed ID: 21949518
[TBL] [Abstract][Full Text] [Related]
47. Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients' Perspectives.
Willems LM; Rosenow F; Schubert-Bast S; Kurlemann G; Zöllner JP; Bast T; Bertsche A; Bettendorf U; Ebrahimi-Fakhari D; Grau J; Hahn A; Hartmann H; Hertzberg C; Hornemann F; Immisch I; Jacobs J; Klein KM; Klotz KA; Kluger G; Knake S; Knuf M; Marquard K; Mayer T; Meyer S; Muhle H; Müller-Schlüter K; von Podewils F; Ruf S; Sauter M; Schäfer H; Schlump JU; Syrbe S; Thiels C; Trollmann R; Wiemer-Kruel A; Wilken B; Zukunft B; Strzelczyk A
CNS Drugs; 2021 Oct; 35(10):1107-1122. PubMed ID: 34275102
[TBL] [Abstract][Full Text] [Related]
48. Genetics of tuberous sclerosis complex: implications for clinical practice.
Caban C; Khan N; Hasbani DM; Crino PB
Appl Clin Genet; 2017; 10():1-8. PubMed ID: 28053551
[TBL] [Abstract][Full Text] [Related]
49. Mammalian Target of Rapamycin Inhibitors and Life-Threatening Conditions in Tuberous Sclerosis Complex.
Moavero R; Romagnoli G; Graziola F; Curatolo P
Semin Pediatr Neurol; 2015 Dec; 22(4):282-94. PubMed ID: 26706015
[TBL] [Abstract][Full Text] [Related]
50. Bilateral Renal Angiomyolipomas and Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex: a Case Report and Review of The Literature.
Rambabova Bushljetik I; Lazareska M; Barbov I; Stankov O; Filipce V; Spasovski G
Balkan J Med Genet; 2020 Nov; 23(2):93-98. PubMed ID: 33816078
[TBL] [Abstract][Full Text] [Related]
51. Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2.
Kwiatkowski DJ; Palmer MR; Jozwiak S; Bissler J; Franz D; Segal S; Chen D; Sampson JR
Eur J Hum Genet; 2015 Dec; 23(12):1665-72. PubMed ID: 25782670
[TBL] [Abstract][Full Text] [Related]
52. Targeting the EGFR pathway: An alternative strategy for the treatment of tuberous sclerosis complex?
Schachenhofer J; Gruber VE; Fehrer SV; Haider C; Glatter S; Liszewska E; Höftberger R; Aronica E; Rössler K; Jaworski J; Scholl T; Feucht M
Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12974. PubMed ID: 38562027
[TBL] [Abstract][Full Text] [Related]
53. Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review.
Sadowski K; Kotulska K; Schwartz RA; Jóźwiak S
J Eur Acad Dermatol Venereol; 2016 Apr; 30(4):586-94. PubMed ID: 26403211
[TBL] [Abstract][Full Text] [Related]
54. Tuberous sclerosis complex.
Hasbani DM; Crino PB
Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
[TBL] [Abstract][Full Text] [Related]
55. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
Brakemeier S; Bachmann F; Budde K
Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
[TBL] [Abstract][Full Text] [Related]
56. TSC2 somatic mosaic mutation, including extra-tumor tissue, may be the developmental cause of solitary subependymal giant cell astrocytoma.
Sasaki T; Uda T; Kuki I; Kunihiro N; Okazaki S; Niida Y; Goto T
Childs Nerv Syst; 2022 Jan; 38(1):77-83. PubMed ID: 34741623
[TBL] [Abstract][Full Text] [Related]
57. An updated meta-analysis of effectiveness and safety of mTOR inhibitors in the management of tuberous sclerosis complex patients.
Liu M; Ye J; You X
Childs Nerv Syst; 2024 Mar; 40(3):823-829. PubMed ID: 37906297
[TBL] [Abstract][Full Text] [Related]
58. Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report.
Tarasewicz A; Dębska-Ślizień A; Bułanowski M; Więcek A; Rutkowski B
Transplant Proc; 2014 Oct; 46(8):2912-5. PubMed ID: 25380949
[TBL] [Abstract][Full Text] [Related]
59. Recommendations for the radiological diagnosis and follow-up of neuropathological abnormalities associated with tuberous sclerosis complex.
Rovira À; Ruiz-Falcó ML; García-Esparza E; López-Laso E; Macaya A; Málaga I; Vázquez É; Vicente J
J Neurooncol; 2014 Jun; 118(2):205-223. PubMed ID: 24771286
[TBL] [Abstract][Full Text] [Related]
60. Brain lesions in tuberous sclerosis complex. Review.
Grajkowska W; Kotulska K; Jurkiewicz E; Matyja E
Folia Neuropathol; 2010; 48(3):139-49. PubMed ID: 20924998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
